Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Treating Obesity: Altimmune Announces Positive Topline Results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Altimmune Positive Topline Results Altimmune ( ALT ) announced positive results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide. Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver fibrosis. The Company’s lead product...

December 2, 2023

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority for researchers to create a treatment for them. Patients who are afflicted with untreatable deadly diseases might not have a single drop of hope...

July 20, 2023

Halozyme Therapeutics' Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

The way drugs are being delivered into patients’ bodies have become more than ever considered important with regard to the safety and efficacy of the treatments. We consider Halozyme Biopharmaceutical is a leader in bringing disruptive solutions to significantly improve patient...

July 21, 2023

BioMarin Pharmaceutical Inc Product VOXZOGO® is the First to Prevent Dwarfism in Europe

The most important news in biological sciences is the high degree of success the biological revolution can reach. We can feel the great value every time an untreatable, devastating condition is successfully treated thanks to discoveries made possible through the...

August 31, 2021

The U.S. FDA Approved Novartis Product Fabhalta® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Novartis Approval Novartis ( NVS ) product Fabhalta ( iptacopan ) is a Factor B inhibitor that acts in the proximate alternative complement pathway of the immune system, It provides comprehensive control of red blood cell ( RBC ) destruction...

December 6, 2023

Finally, Gene Editing Therapy Has Been Approved! So Why the Stock Selloff?

Crispr Therapeutics and Vertex Pharmaceuticals Gene Editing Therapey Will Be Marketed On Nov. 16, 2023, Crispr Therapeutics ( CRSP ) and Vertex Pharmaceuticals ( VRTX ) announced that for the first time CRISPR/Cas9 Gene-Edited Therapy will be marketed. On that...

December 11, 2023

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

TG Therapeutics Conference Call TG Therapeutics ( TGTX ) announced that, tomorrow, Tuesday, August 1, 2023, a conference call will be held at 8.30 AM ET, to discuss the results of the second quarter 2023 and provide a business outlook...

July 31, 2023

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals Q2 Financial Results On August 09, 2023 , Xenon Pharmaceuticals ( XENE ) reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. Xenon report started with Mr. Ian Mortimer, the firm’s President and Chief...

August 15, 2023

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

Nuvectis Pharma Nuvectis Pharma ( NVCT ) is a biopharmaceutical company focused on developing innovative precision targeted drugs capable of treating cancers that have yet to find treatments. The Company’s pipeline comprises two drug candidates, NXP800 and NXP900. NXP800 is...

August 20, 2023

Anavex Life Sciences Product Blarcamesine for Alzheimer’s Disease Receives Promising News from the EMA

Anavex Life Sciences Promising News From Anavex Life Sciences ( AVXL ) we learned that The Committee for Medicinal Products for Human Use ( CHMP ) within the European Medicines agency ( EMA ) agreed that oral blarcamesine for Alzheimer’s disease is...

December 20, 2023

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024